Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Bayer now present in four of the largest biotechnology hubs in the United States
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Bayer will be setting up 27 telemedicine centres in 12 districts across 8 states with implementing partners Telerad RxDx and Piramal Swasthya
Subscribe To Our Newsletter & Stay Updated
